OXALIPLATIN Drug Patent Profile
✉ Email this page to a colleague
When do Oxaliplatin patents expire, and when can generic versions of Oxaliplatin launch?
Oxaliplatin is a drug marketed by Accord Hlthcare, Actavis, Actavis Totowa, Am Regent, Chartwell Molecular, Eugia Pharma, Fresenius Kabi Oncol, Fresenius Kabi Usa, Gland, Gland Pharma Ltd, Hengrui Pharma, Hospira Inc, Hospira Worldwide, Meitheal, Mylan Labs Ltd, Norvium Bioscience, Novast Labs, Qilu Pharm Hainan, Sandoz, Sun Pharm, and Teva Pharms. and is included in twenty-seven NDAs.
The generic ingredient in OXALIPLATIN is oxaliplatin. There are twenty-six drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Oxaliplatin
A generic version of OXALIPLATIN was approved as oxaliplatin by HOSPIRA WORLDWIDE on August 7th, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OXALIPLATIN?
- What are the global sales for OXALIPLATIN?
- What is Average Wholesale Price for OXALIPLATIN?
Summary for OXALIPLATIN
| US Patents: | 0 |
| Applicants: | 21 |
| NDAs: | 27 |
| Finished Product Suppliers / Packagers: | 18 |
| Raw Ingredient (Bulk) Api Vendors: | 28 |
| Clinical Trials: | 2,082 |
| Patent Applications: | 406 |
| Drug Prices: | Drug price information for OXALIPLATIN |
| What excipients (inactive ingredients) are in OXALIPLATIN? | OXALIPLATIN excipients list |
| DailyMed Link: | OXALIPLATIN at DailyMed |
Recent Clinical Trials for OXALIPLATIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Oncotelic Inc. | Phase 2/Phase 3 |
| State University of New York - Downstate Medical Center | Phase 1/Phase 2 |
| Peking University | N/A |
Pharmacology for OXALIPLATIN
| Drug Class | Platinum-based Drug |
Anatomical Therapeutic Chemical (ATC) Classes for OXALIPLATIN
Paragraph IV (Patent) Challenges for OXALIPLATIN
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ELOXATIN | Injection | oxaliplatin | 5 mg/mL, 40 mL vials | 021759 | 1 | 2007-07-16 |
| ELOXATIN | Injection | oxaliplatin | 5 mg/mL, 10 mL and 20 mL vials | 021759 | 11 | 2007-02-09 |
US Patents and Regulatory Information for OXALIPLATIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novast Labs | OXALIPLATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 207562-001 | Oct 16, 2018 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hospira Worldwide | OXALIPLATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 078813-001 | Aug 7, 2009 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sandoz | OXALIPLATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 078817-001 | Jan 24, 2011 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Pharms | OXALIPLATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 022160-002 | Aug 7, 2009 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
